IMPRIMIS PHARMACEUTICALS INC

Inactive Instrument

Analyst Reco. Imprimis Pharmaceuticals Inc Nasdaq

Equities

US45323A2015

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating	Nov. 14	MT
B. Riley Raises Harrow Health's PT to $45 From $42 on Heels of Announced Transactions With Santen, Novaliq; Keeps Buy Rating	23-07-20	MT
B. Riley Raises Harrow Health's Price Target to $42 From $24, Keeps Buy Rating	23-05-04	MT
Lake Street Adjusts Price Target on Harrow Health to $37 From $24, Maintains Buy Rating	23-04-17	MT
B. Riley Lifts Harrow Health's PT to $24 From $22 Accounting for Additional Incremental Revenues From Fab-Five Products, Ramp Up of IHEEZO Sales Trajectory in 2024; Keeps Buy Rating	23-03-27	MT
B. Riley Raises Harrow Health's PT to $22 From $17 on Heels of Acquisition of 5 New Ophthalmology Products, Keeps Buy Rating	23-01-05	MT
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and 'BB' Rating from Egan-Jones	22-12-15	AQ
B. Riley Securities Resumes Harrow Health at Buy with $17 Price Target, Says Well-Positioned to Maintain Robust Momentum	22-09-08	MT
B. Riley Raises Harrow Health's Price Target to $20 from $17 After Higher-than-Expected Q1 Revenue, Keeps Buy Rating	22-05-20	MT
HARROW HEALTH : B. Riley Resumes Harrow Health at Buy with $16 PT, Says Well-Positioned to Maintain Momentum with Recent Q2 Beat, M&A Execution	21-10-14	MT
HARROW HEALTH : Aegis Capital Starts Harrow Health at Buy with $15 Price Target	21-09-24	MT
Harrow Health : Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones (Form 8-K)	21-06-14	PU
HARROW HEALTH : B. Riley Adjusts Harrow Health's Price Target to $14 From $12, Keeps Buy Rating	21-01-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer